CPHI & PMEC India 2024 stages the future of pharmaceuticals with innovation

By Staff Report November 27, 2024 2:44 pm IST

 CPHI & PMEC India 2024 showcased over 10,000 products, creating a unique platform for collaboration and driving innovation in the pharmaceutical industry.

The 17th edition of CPHI & PMEC India, is being held at the India Expo Centre, Greater Noida, Delhi-NCR, showcasing the robust potential of India’s pharmaceutical industry. With the Indian pharma market projected to grow to USD 130 billion by 2030 and USD 450 billion by 2047, the event highlighted the industry’s vital role in shaping global healthcare. Bringing together over 2,000 exhibitors and 50,000 visitors from more than 150 countries, including the USA, UAE, South Korea, Japan, and the United Kingdom, the expo serves as a dynamic hub for innovation and collaboration. Spanning pharma machinery, packaging, analytical instruments, laboratory technologies, ingredients, and beyond, it offers a comprehensive platform for stakeholders to engage in transformative dialogues and foster strategic partnerships.

Key dignitaries such as  K. Raja Bhanu, Director General, Pharmexcil; Harish K. Jain, President, FOPE (Federation of Pharma Entrepreneurs);  Namit Joshi, Vice Chairman, Pharmexcil; AVPS Chakravarthy, Global Ambassador, WPO;  Rhonda Duffy, Executive Vice President and COO, Biocon Biologics;  Rakesh Kumar, Chairman, India Expo Mart Limited (IEML) & Director General, Export Promotion Council for Handicrafts (EPCH); R.K. Jain, Chairman, CPI; Ranjana Ganguly, Board Member, PCSI; Yogesh Mudras, Managing Director, Informa Markets in India, Wouter Moulman, Chief Commercial Officer, Informa Markets, IMEA, Adam Anderson, Executive Vice President – Pharma, Informa Markets B.V.;  and Rahul Deshpande, Sr. Group Director, Informa Markets in India, did the honours, amidst an august industry presence.

The event featured a stellar lineup of exhibitors, including leading names like Dr. Reddy’s Laboratories Ltd, Biocon Ltd, Glenmark Lifesciences Ltd, Morepen Laboratories Ltd, Hetero Labs Limited, Lupin Ltd, Signet Excipients Pvt. Ltd, Apitoria Pharma Pvt Ltd, Capsugel Healthcare Pvt. Ltd, Supriya Lifescience Ltd, SMS Pharmaceuticals Ltd, MSN Laboratories Pvt. Ltd, Sekhmet Pharmaventures Pvt. Ltd, Tirupati Lifesciences Pvt. Ltd, and Merck Life Science Pvt. Ltd, among others. The PMEC pavilion showcases cutting-edge pharmaceutical manufacturing technologies, with prominent exhibitors like ACG, Accupack Engineering, Ace Technologies, Avish Machines, Bowman & Archer Pharma Machines, Cadmach Machinery, CAM PAK India, Fette India, IMA Industria Macchine, Parle Global Technologies, Snowbell Machines, and Truking Technology, spotlighting the latest advancements in equipment and innovation.

This year, the expo garnered strong support from prominent industry associations, including CIPI, FOPE (Federation of Pharma Entrepreneurs), IPEC India, and Pharmexcil, further cementing its status as a leading and highly anticipated event in the pharmaceutical industry.

 AVPS Chakravarthy, Global Ambassador, WPO, said, “The Indian pharmaceutical industry is demonstrating its innovative potential through advancements like Carticel therapy for cancer treatment and Nafithromycin, a groundbreaking macrolide antibiotic tackling drug-resistant pathogens. These innovations highlight India’s dual strengths in affordability and efficacy, reaffirming its role as the ‘pharmacy of the world.’ Events like CPHI & PMEC India provide vital platforms for collaboration, showcasing progress in AI-driven drug inspection, sustainable packaging, and startup-driven innovations, propelling the industry towards a future of higher value creation and global leadership in both volume and value.”

Dr. Veeramani, Chairman, Pharmexcil, said “The Indian pharmaceutical industry stands as a global leader, exporting to over 200 countries and providing comprehensive solutions across APIs, finished dosages, clinical research, and pharmacovigilance. With platforms like CPHI showcasing India’s capabilities, the sector is poised for transformative growth—from its current $55 billion to a projected $130 billion by 2030 and $450 billion by 2047. Innovations in biologics, specialty generics, and the impact of policies like the U.S. Biosecure Act underline the industry’s potential to redefine healthcare solutions worldwide.”

K. Raja Bhanu, Director General, Pharmexcil, said, “The Indian pharmaceutical sector, a key focus area for exports, has demonstrated remarkable growth, with current market size at $55 billion and exports contributing $27.85 billion. Projections indicate exports will soar to $130 billion by 2030 and $450 billion by 2047. CPHI & PMEC India highlights India’s strengths in manufacturing, analytics, AI, and machine learning.”

Namit Joshi, Vice Chairman, Pharmexil, said, “The Indian pharmaceutical industry has solidified its global position as the ‘Pharmacy of the World’ and earned recognition as the ‘Healers of the World’ through its exceptional contribution to COVID-19 vaccine distribution. With exports nearing $27.84 billion and innovative advancements like nanoparticles and improved drug delivery systems, India continues to lead. Integrating IT with pharmaceuticals will further strengthen its role, paving the way for dominance in biologics and biosimilars. CPHI & PMEC India is instrumental in showcasing this progress and reinforcing India’s potential to serve global healthcare needs.”

Harish K. Jain, President, FOPE (Federation of Pharma Entrepreneurs), said “India’s pharmaceutical industry, valued at $60 billion today, plays a vital role in global exports, with $30 billion of that in exports. By 2030, we expect our exports to grow significantly, with 70% directed to Europe and the US. Our industry’s impact is enormous—Indian pharmaceuticals contribute $8 billion annually to the US healthcare system, saving patients over $1.5 trillion. With growing capabilities in AI, machine learning, and biologics, India is poised to become the world’s leading pharmaceutical hub, targeting a $1 trillion industry by 2047.”

CPHI India features a wide array of exhibitors, including Active Pharmaceutical Ingredients (APIs), antibiotics, antibodies, biocatalysts, biotechnology, excipients, drug formulations, herbal teas, and many more, representing the entire pharmaceutical manufacturing ecosystem. On the other hand, PMEC India highlights innovations in pharmaceutical equipment, including packaging and processing equipment, tableting and capsule fillers, plant/facility equipment, process automation, filtration systems, and much more. Together, these exhibitions provide a holistic view of the advancements and opportunities within the pharma and biopharma industries, driving growth, innovation, and collaboration.